18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy

Completed · Phase 2

Conditions studied: Chronic Traumatic Encephalopathy

In brief

This study will explore the use of flortaucipir as a biomarker for chronic traumatic encephalopathy (CTE) and examine the relationship between clinical presentation and tau deposition.

Key facts

Study ID

NCT02079766

Run by

Avid Radiopharmaceuticals

People needed

41

Starts

2014-06-01

Expected to finish

2015-10-01

Last updated by the study team

2020-09-07

Who can join

Age: any. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Male subjects consented and currently enrolled in the Diagnosing and Evaluating Traumatic Encephalopathy Using Clinical Tests (DETECT) or the Long-Term Consequences of Repetitive Brain Injury in Athletes study protocols
• Can tolerate up to two PET imaging sessions
• Have the ability to provide informed consent for study procedures

You may not qualify if…

• Claustrophobia
• Current clinically significant cardiovascular disease or clinically significant abnormalities on screening ECG
• History of risk factors for Torsades de Pointes or are taking drugs known to cause QT-prolongation
• Current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer that the investigator believes would affect study participation or scan results
• Have had a non-study related radiopharmaceutical imaging or treatment within 7 days prior to study PET imaging sessions

Where it is running

• Banner Alzheimer's Institute — Phoenix, Arizona, United States
• Boston University — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.